We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Down to our last million. ‘Sufficient to finish current work.’ Presumably doesnt include getting Nanogenics in to clinical trials next year. When you consider the cost of a year in the aim market that is pretty tight, but expected. Wonder how they earned £1900? So possible farm out against another raise. It does look like opportunities opening in multiple areas. Gl all
This is exactly the reassurance investors needed.
Well done to the company, this is much better news.
N4P in "advanced stages of finalising a collaboration with an independent global R&D leader based in the US" - RNS today
CEO: "We are closer than ever before to agreeing a collaboration which would see Nuvec® being applied to other technologies with a view to co-marketing the resultant technology to big pharma and I look forward to making further announcements on this in the near future"
Sounds like a transformational announcement in "the near future" is on the way....
Good luck, Brighty
Nigels comment.
"Our IP position has strengthened and we believe we are closer than ever before to agreeing a collaboration which would
see Nuvec® being applied to other technologies with a view to co-marketing the resultant technology to big pharma and I
look forward to making further announcements on this in the near future"
Sounds quite upbeat to me....let's see how things pan out in the coming months gla
Collaborations
· Company continues to seek partners to develop its Nuvec® technology and is in the
advanced stages of finalising a collaboration with an independent global R&D leader based
in the US with the aim of securing a co-marketing agreement following initial studies.
That sounds promising.
I have also seen the glory days of N30p however i simply watched as that slowly disappeared before my eyes.
Yes a few little wins and encouraging news of late. We have seen n4p, n3p, n2p,. n1p and now even n0.6p so hopefully the train will at some point move in the opposite direction.
GLA.
My words are often the kiss of death however we seem to be holding well at .9 of a penny.
25% over the month. i like many of you still have a long way to go before i see any profits but i'm happy to celebrate little wins. i'm hoping the next RNS doesn't bring a downfall as we have seen so many times before.
fingers firmly crossed. 7 years invested here, what's another year or two?
All these 'positive findings' but as of yet zero commercial traction. It's time to deliver for N4P.
All good points.
In the last online presentation by the CEO, he said that any funding would be arranged with any potential partners.
There are many different drug delivery companies trialing in many areas of medicine. I’m not sure it is a one size fits all or winner takes all race. N4p have two very specific vehicles Nanogenics and Nuvec fully patented. Whilst they have partnerships and trials with different universities, they have not got the clout of bill Gates foundation or a European foundation like some competitors in Nanotechnology. Their clinical trials seem further away than some and as yet no licensing agreements , they are conducting their research and trials in different areas to their competitors , specifically with Nanogenics. Oral vaccination seems a much more competitive area, but they could still succeed in that too in some form. Much to play for
The pharma that moves first will get the rewards.
Nuvec looks like the real deal.
Https://invst.ly/14fvom weekly
https://invst.ly/14fvq9 daily
rsi stregth index looking stronger break above 0.90 bring it out of o/s
How can we still be at this stage.
Every update we go backwards!
We’re much further ahead than that.
Look a teeny Aptamer Group RNS this morning partnering with Kairos Biotech, and the size of the market they are targeting.
Nuvec is proving itself, and the patents in all major Global territories make this very interesting indeed.
The mice are all feeling pretty chipper I trust, until the grant runs out at Queensland. Not wishing to be a party pooper but the eternal student syndrome looms large. Still all about university research. Can’t see anything to get excited about until we get to clinical trials next year
Positive news.
Yes, the recent progress on the Nuvec science (including the excellent oral news update today) and the patent coverage (from an IP perspective) makes this an interesting punt at this price and Mcap. The Nanogenics business has also added an extra opportunity for N4P. A licencing deal, as you say, will change everything for N4P's share price and valuation. Today's RNS makes that more likely than ever. 0.82p is a very cheap entry point for newbies.
Phenomenal news that in vivo, Nuvec has a demonstrable positive impact.
More encouraging news today from N4P, regarding Nuvec and its potential to be developed as an oral delivery system for plasmid DNA, mRNA or siRNA.
N4P are talking up Nuvec being used as an application for Irritable Bowel Disease & to treat colonic cancer.
This is a big market for N4P to be chasing. A quick bit of background below:
* About 7 million people worldwide have IBD. The prevalence of IBS among adults is estimated to be 4.1% to 10% globally, with IBS-C accounting for more than one-third of cases.
* Over 500,000 people in the UK have Inflammatory Bowel Disease (IBD), the two main forms of which are Crohn's Disease and Ulcerative Colitis.
* Colon cancer is the second leading cause of cancer-related deaths worldwide. In 2020, more than 1.9 million new cases of colorectal cancer and more than 930 000 deaths due to colorectal cancer were estimated to have occurred worldwide.
At some stage a big pharma is going to take a look at N4P for a partnership as the data is getting better and better. When that happens the share price is going to re-rate. You have to be in it to win it....
Good luck, Brighty
Not much in the RNS !!!
RED day ahead IMHO !!!!
Was expecting sooooo much more !!!
The University of Queensland has informed the Company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec® in India.
The granted patent in India is for a composition of matter patent for the particle itself as well as the manufacturing process relating to how the particle is made and matches the patents granted in the USA, Canada, Europe, Japan, Australia and China.
For a Company that has protected ‘Nuvec’ in all the major Global territories one has to consider the possibility of immense upside on a commercial agreement in the future.
The Company hasn’t gone to the effort & expense of protecting what it has designed, prior to announcing a Potential Partnership/agreement.
Perhaps the market is beginning to attribute some value to what The Company is planning, and protecting.
We now have Nanogenics as well as Nuvec at the cutting edge, both with huge potential.
* More than 75 million people worldwide are affected by Glaucoma = A big opportunity for N4P
* The total Glaucoma treatment market size in 2021 exceeded $5.5 billion and is growing = A big opportunity for N4P
* Other fibrotic treatments are also being targeted by Nanogenics , including for liver and lung fibrosis. = A big opportunity for N4P
In relation to Nuvec we know that:
* The number of approvals of new gene therapies and the need for appropriate delivery systems have reached unprecedented highs and demand is growing rapidly = A big opportunity for N4P
* The AAV vector market alone (AAV based gene therapy and AAV manufacturing) is projected to grow from USD 1.9 billion in 2022 to USD 11.1 billion by 2030 = A big opportunity for N4P
N4P is a slow burner but it it will only take one positive RNS re a licencing deal to change everything for N4P's MCAP and share price....
Good luck, Brighty
19 trades all last week and 37 today before 12 .